The latest update from the US Food and Drug Administration in early March has brought 43 draft new and updated product-specific guidances for generic drug development, comprising 33 new guidances and 10 revised documents.
Among the latest documents are new draft guidances dedicated to besifloxacin hydrochloride suspension and clevidipine emulsion, as well as...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?